Argenica Therapeutics Limited (ASX: AGN) has revealed significant progress in its neuroprotective drug candidate, ARG007, designed to mitigate brain tissue damage in neurological disorders. In a preclinical model of hypoxic-ischaemic encephalopathy (HIE), ARG007 demonstrated remarkable efficacy. The study showcased a 46% reduction in total brain injury compared to a saline placebo and a 42% reduction compared to therapeutic hypothermia 48 hours post-HIE.
Impressively, even 4 weeks after the event, a single dose of ARG007 sustained a 52% reduction in total brain injury compared to saline and a 57% reduction compared to therapeutic hypothermia. These promising results suggest ARG007 could serve as a valuable neuroprotection therapy for HIE, either in conjunction with hypothermia or as a standalone treatment when hypothermia is not feasible. Argenica plans to further validate these findings through larger animal studies and complete essential juvenile toxicology studies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
